ReviewFrontiers in medicine2026
Efficacy and safety of remimazolam for sedation in gastrointestinal endoscopy: a systematic review and meta-analysis.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastrointestinal endoscopy serves as a key tool for diagnosing and treating digestive disorders. Adequate sedation is indispensable in achieving ideal surgical outcomes and promoting patient comfort. Recently, remimazolam has been utilized more frequently because of its good safety features, brief action time and rapid onset. This study aims to systematically review and meta-analyze remimazolam's effectiveness and safety profile in sedating patients undergoing gastrointestinal endoscopies. Methods: We conducted literature searches in Embase, PubMed, and the Cochrane Library databases, covering the period from the establishment of each database to January 31, 2026 for all relevant CCTs and RCTs that discussed remimazolam sedation for gastrointestinal endoscopy. RevMan software (version 5.4) was employed for all statistical analyses. Results: Eight trials involving 2,455 patients were included. In cardiovascular outcomes, remimazolam was linked to a significantly lower hypotension (RR = 0.59; 95% CI: 0.43-0.81) and bradycardia (RR = 0.42; 95% CI: 0.25-0.71) risks compared with midazolam and propofol. For respiratory adverse events, remimazolam demonstrated notably reduced rates of apnea (RR = 0.51; 95% CI: 0.30-0.88), oxygen desaturation (RR = 0.20; 95% CI: 0.08-0.52) and diminished respiratory compromise (RR = 0.45; 95% CI: 0.23-0.87). Regarding patient comfort, remimazolam significantly reduced injection-related pain (RR = 0.20; 95% CI: 0.06-0.66). Conclusion: Remimazolam may confer a favorable safety profile for procedural sedation in adults receiving gastrointestinal endoscopies. It could serve as a reliable and effective alternative to conventional sedatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.